Completing the human genome is great publicity for PacBio's Sequel instruments. The initial Sequel system, introduced in 2018, addressed a long-standing criticism of long-read sequencing: accuracy. The Sequel II introduced hardware and software upgrades and produced eight times the data compared to the previous system. With the Sequel IIe System in October of last year, customers were freed from post-processing data and were able to integrate workflows into the cloud. Wall Street noticed. The stock is up 105% since, outperforming Illumina.